6009-98-9

基本信息
牛磺鹅脱氧胆酸钠盐
2-[(3ALPHA,7ALPHA-DIHYDROXY-24-OXO-5BETA-CHOLAN-24-YL)AMINO]ETHANESULFONIC ACID SODIUM SALT
3ALPHA,7ALPHA-DIHYDROXY-5BETA-CHOLAN-24-OIC ACID N-[2-SULFOETHYL]AMIDE SODIUM SALT
5BETA-CHOLAN-24-OIC ACID N-[2-SULFOETHYL]AMIDE-3ALPHA,7ALPHA-DIOL SODIUM SALT
5BETA-CHOLANIC ACID-3ALPHA,7ALPHA-DIOL-24-N-(2-SULFOETHYL)-AMIDE SODIUM
5-BETA-CHOLANIC ACID-3-ALPHA, 7-ALPHA-DIOL N-(2-SULPHOETHYL)-AMIDE SODIUM SALT
SODIUM TAUROCHENODEOXYCHOLATE
SODIUM TAUROCHENODEOXYCHOLIC ACID
TAUROCHENODEOXYCHOLIC ACID SODIUM
TAUROCHENODEOXYCHOLIC ACID SODIUM SALT
TAUROCHENODESOXYCHOLIC ACID, SODIUM SALT
2-([3α,7α-dihydroxy-24-oxo-5β-cholan-24-yl]amino)ethanesulfonic acid sodium salt
NSC681055
Taurochenodeoxycholic acid sodium salt, 2-([3α,7α-Dihydroxy-24-oxo-5β-cholan-24-yl]amino)ethanesulfonic acid sodium salt, 3α,7α-Dihydroxy-5β-cholan-24-oic acid N-(2-sulfoethyl)amide sodium salt
物理化学性质
熔点 | 165-175 °C |
储存条件 | room temp |
溶解度 | 少许溶于甲醇和水 |
形态 | 固体 |
颜色 | 白色至灰白色 |
BRN | 3901205 |
稳定性 | 吸湿性 |
CAS 数据库 | 6009-98-9(CAS DataBase Reference) |
安全数据
危险性符号(GHS) | ![]() GHS07 |
警示词 | 警告 |
危险性描述 | H335-H315-H319 |
防范说明 | P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P |
安全说明 | 24/25 |
WGK Germany | 3 |
F | 3-10 |
海关编码 | 29309090 |
应用领域
知名试剂公司产品信息
牛磺鹅去氧胆酸钠价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-N1429 | 牛磺鹅去氧胆酸钠 Taurochenodeoxycholic acid sodium salt | 6009-98-9 | 100mg | 500元 |
2025/02/08 | HY-N1429 | 牛磺鹅去氧胆酸钠 Taurochenodeoxycholic acid sodium | 6009-98-9 | 10 mM * 1 mLin DMSO | 550元 |
常见问题列表
Human Endogenous Metabolite
|
Taurochenodeoxycholic acid dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, Taurochenodeoxycholic acid significantly augments PKC mRNA levels, activities and increases JNK, caspase-3 and caspase-8 mRNA expression levels, activities.
Taurochenodeoxycholic acid (0.05, 0.1g/kg) decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2.
Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation.
Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats.